<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1390">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04343144</url>
  </required_header>
  <id_info>
    <org_study_id>APHP200389-5</org_study_id>
    <nct_id>NCT04343144</nct_id>
  </id_info>
  <brief_title>Trial Evaluating Efficacy and Safety of Nivolumab (Optivo®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort.</brief_title>
  <acronym>CORIMUNO-NIVO</acronym>
  <official_title>Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients CORIMUNO-19-Nivolumab Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It appears interesting to use nivolumab in severe patients infected with SARS-CoV-2 requiring
      hospitalization in conventional unit or in ICU.

      This protocol CORIMUNO19-NIVO therefore, will evaluate the efficacy and safety of OPTIVO®
      (nivolumab) COVID-19 patients hospitalized in conventional unit.

      The purpose of this study is to show the efficacy of nivolumab in patients with COVID-19 in
      combination with standard treatments.

      A phase 2 randomized open trial will evaluate the efficacy and safety of optivo® (nivolumab)
      alone versus standard of care (SoC) in patients hospitalized in conventional units.

      Patients will be randomly allocated 1:1 to either nivolumab or SoC.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 15, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2 parallels arms randomized open-label multi center clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to clinical improvement</measure>
    <time_frame>day 14</time_frame>
    <description>the time required for clinical improvement, defined as the time elapsed between randomization and a two-point improvement on an ordinal scale with seven categories (WHO scale), or the discharge alive from hospital, whatever occurred first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of ICU admission</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive nasal PCR</measure>
    <time_frame>day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade 3-4 adverse events</measure>
    <time_frame>day 28</time_frame>
    <description>according to CTC AE-4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>World Health Organisation (WHO) progression scale</measure>
    <time_frame>day 4, 7 and 14</time_frame>
    <description>range, from 0 (healthy) to 10 (death)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>COVID19- Infection With SARS-CoV-2 Virus</condition>
  <arm_group>
    <arm_group_label>Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Card</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab Injection</intervention_name>
    <description>Treatment consists of an infusion of OPDIVO® 3mg/kg on day 1 (D1).</description>
    <arm_group_label>Nivolumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (men and women) age over 18 years old

          -  At least one nasal swab positive for COVID-19 detected by PCR, maximum 7 days prior to
             treatment

          -  Viral pneumonia confirmed by TDM scan

          -  Patients meeting all of the following 3 criteria:

               -  Requiring more than 3L/min of oxygen

               -  WHO progression scale = 5

               -  No NIV or High flow

        Exclusion Criteria:

          -  Patients with active cancer and immunocopromised patients

          -  Known hypersensitivity to nivolumab or to any of their excipients.

          -  Pregnancy

          -  Patient with an autoimmune or inflammatory disease (including but not limited to:
             Crohn's Disease, rheumatoid arthritis, scleroderma, systemic lupus erythematosus,
             Grave's disease). Patients with thyroiditis or vitiligo only could be included.

          -  Patient with a history of thymoma

          -  Patient with a history of solid organ transplantation or a bone marrow transplantation

          -  Patients treated with immune checkpoint inhibitors 3 months prior to the study

          -  Patients who had a history of grade 3 or 4 immune-related adverse events with a
             previous treatment with immune-checkpoint inhibtors

          -  Patients requiring ICU based on Criteria of severity of COVID pneumopathy

          -  Respiratory failure requiring mechanical ventilation or extracorporeal membrane
             oxygenation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jacques Cadranel, MD PhD</last_name>
    <phone>1 56 01 66 73</phone>
    <phone_ext>+33</phone_ext>
    <email>jacques.cadranel@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pneumologie hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jacques Cadranel, MD PhD</last_name>
      <phone>01 56 01 66 73</phone>
      <email>jacques.cadranel@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 9, 2020</study_first_submitted>
  <study_first_submitted_qc>April 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2020</study_first_posted>
  <last_update_submitted>April 12, 2020</last_update_submitted>
  <last_update_submitted_qc>April 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

